secwatch.observer — SEC 8-K summary
======================================

Issuer:     BeOne Medicines Ltd. (ONC)
CIK:        0001651308
Form:       8-K
Filed at:   2024-08-07T23:59:59+00:00
Accession:  0001651308-24-000097
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BeiGene Q2 2024 revenue up 56% to $929M; achieves first non-GAAP operating income
--------------------------------------------------------------------------------

- Total revenue of $929 million, up 56% YoY; BRUKINSA global sales $637M (+107% YoY).
- GAAP operating loss narrowed to $107M from $319M; non-GAAP operating income of $48M (positive inflection point).
- Proposes redomicile from Cayman Islands to Switzerland; opens $800M biologics facility in New Jersey.
- Pipeline: advancing sonrotoclax (BCL2i) and BGB-16673 (BTK degrader); over 15 solid tumor molecules in development.
- BRUKINSA leads BTKi class in U.S. new patient starts across all approved indications.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1651308/000165130824000097/0001651308-24-000097-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1651308/000165130824000097/bgne-20240807.htm
  HTML page:      https://secwatch.observer/filing/0001651308-24-000097

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer